Orris

Acute Lung failure long notes for project work of 10 pages in text form only

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources

ACUTE LUNG FAILURE (ACUTE RESPIRATORY FAILURE)

Comprehensive Long Notes for Project Work

1. INTRODUCTION AND OVERVIEW

Acute lung failure, clinically termed Acute Respiratory Failure (ARF), is one of the most common and life-threatening emergencies encountered in critical care medicine. It represents not a single disease but a syndrome — a final common pathway through which a large and diverse number of conditions disrupt the fundamental functions of the respiratory system. Understanding ARF requires an appreciation of respiratory physiology, the mechanisms by which disease disturbs gas exchange, and the principles that govern both supportive and definitive management.
The respiratory system serves two cardinal functions: (1) oxygenation — the uptake of oxygen (O2) from inspired air into the pulmonary circulation, and (2) ventilation — the elimination of carbon dioxide (CO2) produced by cellular metabolism. Failure of either or both of these functions defines respiratory failure. When that failure develops rapidly — over minutes to days — and represents a substantial departure from the patient's baseline status, it is classified as acute.
Acute respiratory failure is characterized by life-threatening derangements in arterial blood gases and acid-base status. In contrast, chronic respiratory failure is more insidious in onset, allowing compensatory mechanisms such as bicarbonate retention by the kidneys to partially normalize pH despite elevated CO2 levels. The distinction is clinically essential because it guides the urgency and type of intervention required.
Source: Fishman's Pulmonary Diseases and Disorders, 2-Volume Set

2. DEFINITION AND DIAGNOSTIC CRITERIA

Precise definition of ARF anchors clinical decision-making. The condition is defined by two arterial blood gas thresholds measured while breathing ambient air or supplemental oxygen:
Hypoxemic Respiratory Failure (Type I)
  • Arterial oxygen partial pressure (PaO2) less than 60 mm Hg
  • This represents the inflection point of the oxyhemoglobin dissociation curve, below which further decreases in PaO2 produce steep falls in hemoglobin oxygen saturation (SaO2) and arterial oxygen content (CaO2)
  • The alveolar-arterial (A-a) oxygen gradient is typically widened
Hypercapnic Respiratory Failure (Type II)
  • Arterial carbon dioxide partial pressure (PaCO2) greater than 45 mm Hg
  • Accompanied by arterial acidosis with pH less than 7.35
  • Reflects failure of the respiratory pump to maintain adequate alveolar ventilation relative to CO2 production
Practical Considerations Any definition based on absolute gas values is inherently arbitrary. A young climber at high altitude may have a PaO2 below 50 mm Hg and not be in respiratory failure. Conversely, a patient with known chronic obstructive pulmonary disease (COPD) who normally maintains a PaO2 of 55 mm Hg may be in acute failure if that value falls to 40 mm Hg during an exacerbation. The key criterion is a significant change from baseline that renders the patient at risk for end-organ hypoxia.
Even when PaO2 is borderline, tissue oxygen delivery is the true concern. Oxygen delivery (DO2) equals cardiac output multiplied by arterial oxygen content. Therefore, low hemoglobin concentration, reduced cardiac output, or rightward shift of the oxyhemoglobin curve at the tissue level can all produce tissue hypoxia without meeting the strict PaO2 threshold for ARF. Clinicians must always interpret gas values in the context of the whole patient.
The distinction between acute and chronic respiratory failure on blood gas analysis alone may be unreachable. Polycythemia and cor pulmonale signal chronic hypoxemia; abrupt mental status change signals acute onset.
Source: Goldman-Cecil Medicine International Edition; Fishman's Pulmonary Diseases and Disorders

3. CLASSIFICATION

Acute respiratory failure is classified along two intersecting axes: the primary gas exchange abnormality and the underlying pathophysiologic mechanism.

3.1 By Gas Exchange Abnormality

Type I — Hypoxemic Respiratory Failure The dominant feature is inadequate oxygenation with PaO2 < 60 mm Hg. PaCO2 is typically normal or low (because hypoxemia drives compensatory hyperventilation). This type is most commonly caused by parenchymal lung diseases (pneumonia, pulmonary edema, ARDS).
Type II — Hypercapnic (Ventilatory) Respiratory Failure The primary abnormality is failure of alveolar ventilation to clear CO2. PaCO2 rises above 45 mm Hg and acidemia follows. Hypoxemia is also invariably present. This type is caused by disorders of the respiratory pump — the CNS, peripheral nerves, neuromuscular junction, respiratory muscles, or chest wall.
Type III — Perioperative Respiratory Failure A subtype characterized by atelectasis developing during or after surgery. Supine positioning, general anesthesia, abdominal distension, and diaphragmatic dysfunction all contribute.
Type IV — Respiratory Failure in the Setting of Shock Hypoperfusion of respiratory muscles during cardiogenic or distributive shock can precipitate ventilatory failure as the diaphragm becomes ischemic and fatigued.

3.2 By Physiologic Mechanism

The "effector components" of the respiratory system — CNS drive, peripheral nervous system, respiratory muscles and chest wall, airways, and alveoli — each form a layer of potential failure:
  • CNS disorders: suppress neural drive to breathe (drug overdose, stroke, brainstem injury)
  • Peripheral nervous system: impair transmission to respiratory muscles (Guillain-Barré syndrome, phrenic nerve injury)
  • Neuromuscular junction: disrupt motor endplate function (myasthenia gravis, organophosphate toxicity)
  • Respiratory muscles: direct fatigue, malnutrition, hypophosphatemia, hypokalemia
  • Chest wall and pleura: restrictive defects (kyphoscoliosis, large pleural effusion, pneumothorax, abdominal compartment syndrome)
  • Airways: obstructive pathology (acute severe asthma, COPD exacerbation, foreign body)
  • Alveoli and pulmonary interstitium: pneumonia, pulmonary edema (cardiogenic and non-cardiogenic), ARDS, interstitial lung disease exacerbation
Source: Fishman's Pulmonary Diseases and Disorders, 2-Volume Set

4. ETIOLOGY AND CAUSES

The causes of ARF are vast. A practical clinical framework groups them by anatomical compartment:

4.1 Airway Diseases

  • Acute severe bronchial asthma (status asthmaticus)
  • Acute exacerbation of COPD (the most common cause of hypercapnic failure)
  • Acute upper airway obstruction: epiglottitis, angioedema, foreign body aspiration, anaphylaxis
  • Tracheal stenosis

4.2 Parenchymal (Alveolar) Diseases

  • Community-acquired pneumonia — the leading cause of hypoxemic ARF globally
  • Nosocomial and ventilator-associated pneumonia
  • Aspiration pneumonitis and aspiration pneumonia
  • Pulmonary edema — cardiogenic (left ventricular failure, mitral stenosis) or non-cardiogenic (ARDS, capillary leak)
  • Acute Respiratory Distress Syndrome (ARDS) — the most severe form of non-cardiogenic pulmonary edema
  • Diffuse alveolar hemorrhage
  • Acute eosinophilic pneumonia
  • Cryptogenic organizing pneumonia (acute form)
  • Pulmonary contusion (post-traumatic)

4.3 Vascular Diseases

  • Massive pulmonary embolism — causes dead space physiology (high V/Q), right heart failure
  • Fat embolism syndrome
  • Amniotic fluid embolism

4.4 Respiratory Pump Failure (Neuromuscular/Skeletal)

  • Guillain-Barré syndrome — rapid ascending paralysis; up to 30% require mechanical ventilation
  • Myasthenic crisis
  • Acute cervical spinal cord injury
  • Phrenic nerve palsy (post-cardiac surgery)
  • Botulism, tetanus
  • Flail chest (multiple rib fractures)
  • Massive pleural effusion, tension pneumothorax
  • Kyphoscoliosis (exacerbated by intercurrent infection)

4.5 CNS-Mediated Failure of Respiratory Drive

  • Drug overdose (opioids, benzodiazepines, barbiturates)
  • Stroke (particularly brainstem involvement)
  • Traumatic brain injury with increased intracranial pressure
  • Severe hypothyroidism (myxedema coma)
  • Central sleep apnea syndromes

4.6 Systemic and Metabolic Conditions

  • Sepsis — most common precipitant of ARDS; distributive shock impairs respiratory muscle perfusion
  • Multiple trauma — combines shock, pulmonary contusion, and aspiration risk
  • Burns — inhalation injury causes direct airway and parenchymal damage
  • Pancreatitis — a recognized predisposing condition for ARDS
  • Massive blood transfusion (TRALI) — transfusion-related acute lung injury
  • Drowning

5. PATHOPHYSIOLOGY

5.1 Mechanisms of Hypoxemia

Four physiologic mechanisms account for hypoxemia in all clinical contexts:
1. Alveolar Hypoventilation When alveolar ventilation falls, CO2 accumulates and, by the alveolar gas equation, displaces oxygen in the alveolus (PAO2 = PIO2 − PaCO2/R). The hallmark is a normal A-a gradient. Correcting ventilation corrects both the hypercapnia and the hypoxemia. Clinical examples: CNS depression, severe neuromuscular weakness.
2. Ventilation-Perfusion (V/Q) Mismatch This is the most common mechanism of clinically encountered hypoxemia. Lung units receiving blood flow disproportionate to their ventilation (low V/Q units) contribute poorly oxygenated blood to the pulmonary veins. The hypoxemia responds well to supplemental oxygen because increasing inspired O2 can raise PAO2 even in poorly ventilated alveoli. The A-a gradient is widened. Examples: COPD, asthma, pulmonary embolism, pneumonia.
3. Intrapulmonary Shunt Shunt is the extreme of V/Q mismatch — alveoli are completely perfused but not ventilated (V/Q = 0). Deoxygenated mixed venous blood passes unchanged into the arterial circulation. Shunt hypoxemia characteristically does not respond to supplemental oxygen. This is because adding O2 to already collapsed alveoli cannot improve their zero ventilation. Examples: ARDS, lobar pneumonia (complete consolidation), atelectasis. Shunt fraction above 30% generally requires positive pressure ventilation.
4. Diffusion Limitation Reduced transfer of oxygen across the alveolar-capillary membrane due to membrane thickening or reduction in capillary transit time. At rest, diffusion limitation rarely causes hypoxemia even in advanced parenchymal fibrosis; it becomes significant with exercise or in very severe disease. Example: severe interstitial lung disease, advanced emphysema with loss of capillary bed.

5.2 Mechanisms of Hypercapnia

CO2 elimination is governed by the relationship: PaCO2 = (VCO2 × 0.863) / VA, where VA is alveolar ventilation and VCO2 is the rate of CO2 production. Hypercapnia results from one or more of the following:
  • Decreased alveolar ventilation (reduced total ventilation or increased dead space fraction)
  • Increased CO2 production (fever, sepsis, shivering, excessive carbohydrate nutrition)
  • Increased dead space ventilation (alveoli ventilated but not perfused — pulmonary embolism, emphysema, late-phase ARDS)

5.3 Ventilatory Supply and Demand Imbalance

Respiratory failure can be conceptualized as an imbalance between the demand placed on the respiratory pump and its capacity (supply) to meet that demand. Factors that reduce supply include:
  • Respiratory muscle fatigue from high respiratory rates and increased inspiratory work
  • Malnutrition and electrolyte abnormalities (hypophosphatemia, hypokalemia)
  • Reduced diaphragm perfusion in shock or anemia
  • Neuromuscular disease, airflow limitation, reduced lung or chest wall compliance
Factors that increase demand include:
  • Increased dead space (requiring higher total ventilation for the same CO2 clearance)
  • Increased metabolic rate (fever, sepsis, trauma)
  • Increased work of breathing from bronchoconstriction, increased secretions, or decreased lung compliance
When demand exceeds supply, the respiratory muscles fail and ventilatory failure supervenes.

5.4 Pathophysiology of ARDS (the Archetypal Acute Parenchymal Failure)

ARDS represents the most severe form of hypoxemic ARF and is characterized by diffuse bilateral alveolar-capillary injury. Its pathobiology unfolds in three overlapping phases:
Exudative Phase (Days 1–7): Inflammatory mediators (cytokines, activated neutrophils, complement) disrupt the tight junctions of both the alveolar epithelium (type I and II pneumocytes) and the capillary endothelium. Protein-rich edema floods the alveolar spaces, inactivates surfactant, and forms hyaline membranes. The chest radiograph shows bilateral infiltrates and PaO2/FiO2 ratio falls precipitously.
Proliferative Phase (Days 7–14): Type II pneumocytes proliferate to repair the damaged epithelial surface. Alveolar macrophages clear the edema and cellular debris. Surfactant production begins to recover.
Fibrotic Phase (Week 2 onward): In severe cases, fibroblast proliferation leads to progressive interstitial and intra-alveolar fibrosis, further reducing lung compliance and gas exchange.
The Berlin Definition (2012) stratifies ARDS by severity based on the PaO2/FiO2 (P/F) ratio with PEEP ≥ 5 cm H2O:
  • Mild ARDS: P/F 201–300 mm Hg
  • Moderate ARDS: P/F 101–200 mm Hg
  • Severe ARDS: P/F ≤ 100 mm Hg
Source: Goldman-Cecil Medicine International Edition; Fishman's Pulmonary Diseases and Disorders

6. CLINICAL FEATURES AND DIAGNOSIS

6.1 Symptoms

The presenting symptoms of ARF reflect both the primary etiology and the secondary effects of hypoxemia and hypercapnia on organ systems:
Due to Hypoxemia:
  • Dyspnea (the cardinal symptom — subjective breathlessness)
  • Air hunger; inability to complete sentences
  • Tachypnea (respiratory rate > 20–25 breaths/min is a hallmark)
  • Central cyanosis (visible when reduced hemoglobin > 5 g/dL — a late sign; unreliable in anemia)
  • Restlessness, agitation, confusion (brain is exquisitely sensitive to hypoxia)
  • Tachycardia
Due to Hypercapnia:
  • Headache (CO2 causes cerebral vasodilation)
  • Drowsiness progressing to stupor and coma (CO2 narcosis)
  • Asterixis (flapping tremor)
  • Flushed warm peripheries (due to vasodilation)
  • Raised jugular venous pressure and papilledema (in severe chronic cases)
Due to Increased Work of Breathing:
  • Use of accessory muscles (sternocleidomastoid, scalene muscles)
  • Intercostal and subcostal recession
  • Nasal flaring
  • Paradoxical abdominal movement (abdomen moves inward during inspiration — sign of diaphragmatic fatigue)
  • Tripod positioning

6.2 Physical Examination

Examination findings are largely determined by the underlying etiology:
  • Diffuse wheeze: asthma or COPD
  • Coarse crepitations: pulmonary edema, pneumonia
  • Dull percussion: pleural effusion, lobar consolidation
  • Absent breath sounds: pneumothorax, large effusion
  • Stridor: upper airway obstruction
  • Barrel chest with prolonged expiration: COPD
  • Focal signs: unilateral consolidation (pneumonia), deviated trachea (tension pneumothorax)

6.3 Investigations

Arterial Blood Gas (ABG) Analysis — the cornerstone of diagnosis
  • PaO2, PaCO2, pH, HCO3− (calculated), SaO2
  • Alveolar-arterial oxygen gradient: P(A-a)O2 = [FiO2 × (Patm − 47) − PaCO2/0.8] − PaO2
    • Normal A-a gradient: < 10–15 mm Hg at room air (increases with age and FiO2)
    • Widened A-a gradient indicates an intrinsic pulmonary problem (V/Q mismatch, shunt, diffusion impairment)
    • Normal A-a gradient with elevated PaCO2 indicates pure hypoventilation
  • PaO2/FiO2 (P/F) ratio: < 300 = acute lung injury; < 200 = ARDS (older criteria)
Pulse Oximetry
  • Continuous, non-invasive monitoring of SaO2
  • Reliable above SaO2 88%; underestimates severity of hypoxemia in the presence of carboxyhemoglobin, methemoglobin, severe anemia
Chest Radiograph
  • Portable AP in ICU setting
  • Unilateral infiltrate: pneumonia, atelectasis, contusion
  • Bilateral infiltrates with Kerley B lines and cardiomegaly: cardiogenic pulmonary edema
  • Bilateral infiltrates with normal cardiac silhouette: ARDS
  • Hyperinflation: COPD, asthma
  • Air under diaphragm: pneumoperitoneum (though not directly causing ARF)
High-Resolution CT (HRCT) of Chest
  • More sensitive for subtle parenchymal disease
  • In ARDS: dependent consolidation, non-dependent ground-glass opacification (heterogeneous lung injury)
  • Rules out occult pneumothorax, PE, or occult mass
Echocardiography
  • Bedside point-of-care echo differentiates cardiogenic from non-cardiogenic pulmonary edema
  • Assesses left ventricular function, right ventricular strain (suggesting PE or severe ARDS)
  • Identifies pericardial effusion, valvular disease
Complete Blood Count, Metabolic Panel, Cultures
  • White cell count and differential: infection vs. inflammatory cause
  • Procalcitonin, CRP: severity markers of infection
  • Lactate: marker of tissue hypoxia and circulatory failure
  • Blood, sputum, urine cultures before antibiotics
  • BNP/NT-proBNP: elevated in cardiogenic causes
Pulmonary Function Tests — limited utility in the acute setting but useful in recovery phase to assess residual lung function
Source: Goldman-Cecil Medicine International Edition

7. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) — A SPECIAL FORM

ARDS merits detailed discussion as it represents the prototypical severe acute lung failure encountered in the ICU.

7.1 Epidemiology

ARDS affects approximately 200,000 patients annually in the United States. Mortality ranges from 30–40% overall, rising to over 45% in severe ARDS. Survivors frequently have persistent functional impairment, cognitive deficits, and psychological morbidity (post-intensive care syndrome).

7.2 Causes (Direct and Indirect)

Direct pulmonary causes ("pulmonary ARDS"):
  • Pneumonia (bacterial, viral, fungal)
  • Aspiration of gastric contents
  • Pulmonary contusion
  • Near-drowning
  • Inhalation injury
Indirect (extrapulmonary) causes:
  • Sepsis (most common overall precipitant — accounts for ~40% of cases)
  • Non-pulmonary trauma with shock
  • Pancreatitis
  • Massive blood transfusion / TRALI
  • Burns
  • Cardiopulmonary bypass

7.3 Berlin Diagnostic Criteria (2012)

  1. Timing: Onset within 1 week of a known clinical insult or new or worsening respiratory symptoms
  2. Chest imaging: Bilateral opacities on CXR or CT not fully explained by effusions, lobar collapse, or nodules
  3. Origin of edema: Respiratory failure not fully explained by cardiac failure or fluid overload (objective assessment with echo needed if no risk factor)
  4. Oxygenation (with PEEP ≥ 5 cm H2O):
    • Mild: PaO2/FiO2 201–300 mm Hg
    • Moderate: PaO2/FiO2 101–200 mm Hg
    • Severe: PaO2/FiO2 ≤ 100 mm Hg

8. MANAGEMENT OF ACUTE RESPIRATORY FAILURE

Management of ARF integrates three simultaneous goals: (1) correct life-threatening hypoxemia, (2) reverse or treat the underlying cause, and (3) support organ systems while recovery occurs.

8.1 General Principles

Airway Management The first priority in any patient with ARF is ensuring a patent airway. If the patient cannot protect the airway (absent gag reflex, deteriorating consciousness, facial burns with evolving edema, stridor suggesting imminent obstruction), early endotracheal intubation is mandatory. Delaying intubation until the patient is in extremis significantly increases procedural risk (hypoxic cardiac arrest during laryngoscopy).
Supplemental Oxygen For all patients not requiring immediate intubation:
  • Nasal cannula: delivers FiO2 up to ~0.44 at flow rates of 1–6 L/min
  • Simple face mask: FiO2 0.35–0.50 at 6–10 L/min
  • Non-rebreather mask with reservoir: FiO2 up to 0.90 at 10–15 L/min
  • High-Flow Nasal Cannula (HFNC): Delivers up to 60 L/min of heated, humidified gas with adjustable FiO2 (0.21–1.0). Reduces nasopharyngeal dead space, provides a degree of positive pressure, and is better tolerated than masks. Increasingly used as first-line for hypoxemic ARF, particularly in COVID-19 pneumonia.

8.2 Non-Invasive Positive Pressure Ventilation (NIV/NIPPV)

NIV delivers positive pressure ventilation via a tight-fitting face or nasal mask, avoiding endotracheal intubation.
Modes:
  • CPAP (Continuous Positive Airway Pressure): Single pressure throughout the respiratory cycle. Recruits collapsed alveoli and reduces shunt. Particularly effective in cardiogenic pulmonary edema — reduces preload and afterload as well as improving gas exchange.
  • BiPAP (Bilevel Positive Airway Pressure): Higher pressure during inspiration (IPAP) and lower pressure during expiration (EPAP). Augments tidal volume, reduces the work of breathing, and assists CO2 clearance.
Established indications for NIV:
  • Acute exacerbation of COPD with hypercapnic failure (strongest evidence: reduces intubation rate and mortality)
  • Acute cardiogenic pulmonary edema
  • Immunocompromised patients with ARF (avoids infectious complications of intubation)
  • Post-extubation respiratory insufficiency in selected patients
Contraindications to NIV (require invasive ventilation instead):
  • Inability to protect airway / absent gag reflex
  • Severe agitation or altered consciousness
  • Inability to tolerate mask (facial trauma, burns)
  • Hemodynamic instability
  • Recent facial, esophageal, or gastric surgery
  • Copious secretions that patient cannot clear
NIV failure (defined as worsening gas exchange, escalating distress, or hemodynamic deterioration despite 1–2 hours of optimal NIV) mandates prompt endotracheal intubation.

8.3 Invasive Mechanical Ventilation

When NIV is contraindicated, fails, or the clinical picture warrants immediate intubation, invasive mechanical ventilation via an endotracheal tube or tracheostomy is initiated.
Key Ventilator Settings:
  • Mode: Assist-Control (volume-controlled or pressure-controlled) is most common in the acute phase
  • Tidal Volume (Vt): The ARDS Network (ARDSnet) landmark trial demonstrated that limiting tidal volumes to 6 mL/kg predicted body weight (PBW) — rather than the previously standard 12 mL/kg — reduces mortality by 22% in ARDS. Even patients without ARDS benefit from lung-protective ventilation.
  • Plateau Pressure (Pplat): Should be kept below 30 cm H2O to prevent ventilator-induced lung injury (VILI) from overdistension.
  • PEEP (Positive End-Expiratory Pressure): Applied to prevent cyclic alveolar collapse and re-opening (atelectrauma). In ARDS, higher PEEP strategies maintain alveolar recruitment but must be balanced against hemodynamic effects (reduced venous return). The ARDSnet protocol provides PEEP/FiO2 tables as guidance.
  • FiO2: Titrated to maintain PaO2 55–80 mm Hg or SaO2 88–95% (permissive range in ARDS to limit oxygen toxicity)
  • Respiratory Rate: Set to approximate baseline minute ventilation (max 35 breaths/min). Permissive hypercapnia (allowing PaCO2 to rise to 50–60 mm Hg) is acceptable to protect lungs from VILI.
  • Inspiratory Flow Rate: Set above patient's demand (usually > 80 L/min) to prevent patient-ventilator dyssynchrony.
ARDSnet Protocol Summary (Table 90-8):
  • Calculate Predicted Body Weight: Male = 50 + 2.3(height in inches − 60); Female = 45.5 + 2.3(height in inches − 60)
  • Initial Vt: 8 mL/kg PBW → reduce by 1 mL/kg every 2 hours to target of 6 mL/kg PBW
  • If Pplat > 30 cm H2O: decrease Vt by 1 mL/kg (minimum 4 mL/kg)
  • If pH ≤ 7.30: increase RR (max 35); if pH < 7.15: consider sodium bicarbonate or cautiously increase Vt

8.4 Adjunctive Strategies in ARDS

Prone Positioning Placing the mechanically ventilated patient in the prone position redistributes lung stress, recruits dorsal atelectatic lung units, and improves V/Q matching. The PROSEVA trial demonstrated a significant mortality reduction (16% vs. 32.8%) when prone positioning was applied for > 16 hours per day in patients with severe ARDS (P/F < 150). It is now a standard of care for severe ARDS.
Neuromuscular Blockade Early short-term continuous neuromuscular blockade (48 hours) with cisatracurium in moderate-to-severe ARDS was associated with improved survival in the ACURASYS trial. However, the subsequent ROSE trial (2019) found no benefit. Current evidence does not support routine early paralysis; it remains an option for refractory dyssynchrony or severe hypoxemia.
Corticosteroids Methylprednisolone has been studied in ARDS to attenuate the inflammatory cascade. Evidence remains mixed. Current evidence (including recent meta-analyses) suggests potential benefit in moderate-to-severe ARDS, particularly when started early. Corticosteroids are more firmly established in specific causes of ARF: acute severe asthma, COPD exacerbation, Pneumocystis jirovecii pneumonia, and organizing pneumonia.
Fluid Management The FACTT trial demonstrated that a conservative fluid strategy (targeting a CVP of 4–6 mmHg) in ARDS reduced days on the ventilator and in the ICU compared to a liberal strategy, without increasing renal failure. The principle: minimize alveolar flooding by avoiding unnecessary fluid administration once hemodynamics are stabilized.
Inhaled Vasodilators Inhaled nitric oxide (NO) and inhaled prostacyclin cause selective pulmonary vasodilation in ventilated lung units, improving V/Q matching and temporarily boosting PaO2. Neither has demonstrated mortality benefit, but both are used as rescue therapy in refractory hypoxemia.
Extracorporeal Membrane Oxygenation (ECMO) Veno-venous ECMO (VV-ECMO) provides extracorporeal gas exchange, allowing the lungs to rest and recover while preventing further VILI. It is reserved for severe ARDS unresponsive to conventional ventilation (P/F < 80 or pH < 7.25 with hypercapnia). The CESAR trial supported its use in specialized centers, though patient selection criteria remain evolving.
Source: Goldman-Cecil Medicine International Edition

9. SPECIFIC MANAGEMENT BY ETIOLOGY

9.1 COPD Exacerbation

  • Controlled low-flow oxygen (target SaO2 88–92% to avoid suppressing hypoxic drive and worsening hypercapnia)
  • Bronchodilators: nebulized short-acting beta-2 agonists (salbutamol) and short-acting anticholinergics (ipratropium) — combination therapy
  • Systemic corticosteroids: prednisolone 40 mg/day for 5 days reduces treatment failure, length of stay, and re-exacerbation rate
  • Antibiotics: indicated when purulent sputum, increased dyspnea, and increased sputum volume are present (Anthonisen criteria)
  • NIV (BiPAP): first-line for pH < 7.35 with PaCO2 > 45 mm Hg — reduces intubation rate by 50% and mortality by ~50%
  • Intubation and ventilation if NIV fails; avoid high PEEP in auto-PEEP prone patients

9.2 Acute Severe Asthma (Status Asthmaticus)

  • Oxygen to maintain SaO2 ≥ 92%
  • Repeated doses of inhaled short-acting beta-2 agonists (salbutamol via nebulizer or MDI + spacer every 20 minutes)
  • Inhaled ipratropium added for synergistic bronchodilation
  • IV/IM corticosteroids: prednisolone or hydrocortisone — reduce inflammation, restore beta-receptor responsiveness
  • IV magnesium sulfate 2 g over 20 minutes: relaxes smooth muscle, reduces admission rate in moderate-to-severe asthma
  • Heliox (helium-oxygen mixture): reduces turbulent airflow resistance in severe obstruction
  • Intubation is high-risk in asthma (risk of severe auto-PEEP, barotrauma, cardiovascular collapse); must be done by experienced physician with ketamine as induction agent (bronchodilating properties)

9.3 Acute Cardiogenic Pulmonary Edema

  • Upright positioning (reduces preload)
  • CPAP or NIV: reduces preload and afterload, recruits alveoli
  • Intravenous diuretics (furosemide): rapidly reduces preload by venodilation before diuresis begins, then reduces edema by diuresis
  • Vasodilators (IV nitroglycerin, nitroprusside): for hypertensive pulmonary edema
  • Morphine: historically used to reduce anxiety and preload, now controversial
  • Address underlying cause: rate control for AF, revascularization for ACS, IABP or LVAD for cardiogenic shock

9.4 Pneumonia

  • Supplemental oxygen; HFNC or NIV for moderate hypoxemia
  • Antibiotics within 1 hour of presentation in severe CAP: empiric regimen targeting most likely pathogens (beta-lactam + macrolide, or fluoroquinolone monotherapy)
  • ICU admission criteria: CURB-65 score ≥ 3, or PSI Class IV-V, or any minor severe criteria
  • Mechanical ventilation if fails to maintain oxygenation

9.5 Tension Pneumothorax

  • Immediate needle thoracostomy (2nd intercostal space, mid-clavicular line) for life-threatening hemodynamic collapse — do not wait for CXR
  • Follow with formal chest drain insertion (4th/5th intercostal space, mid-axillary line)

10. COMPLICATIONS, PROGNOSIS, AND LONG-TERM OUTCOMES

10.1 Complications of Mechanical Ventilation

Ventilator-Induced Lung Injury (VILI) The major iatrogenic harm of mechanical ventilation. Mechanisms include:
  • Volutrauma: overdistension of alveoli by excessive tidal volumes
  • Barotrauma: alveolar rupture from elevated pressure (pneumothorax, pneumomediastinum, subcutaneous emphysema)
  • Atelectrauma: cyclic opening and closing of alveoli causing shear stress on alveolar walls
  • Biotrauma: mechanical injury triggers local cytokine release that propagates systemic inflammation and multi-organ dysfunction
Lung-protective ventilation (6 mL/kg Vt, Pplat ≤ 30 cm H2O, optimal PEEP) is the primary strategy to prevent VILI.
Ventilator-Associated Pneumonia (VAP) Bacterial colonization of the lower respiratory tract after 48–72 hours of intubation. Incidence is 9–27% of ventilated patients. Prevention bundles include:
  • Head-of-bed elevation 30–45°
  • Daily sedation interruption ("sedation vacation") and daily spontaneous breathing trials
  • Regular oral decontamination with chlorhexidine
  • Subglottic secretion drainage
  • Careful hand hygiene Treatment requires broad-spectrum antibiotics guided by tracheal aspirate culture and local antibiogram.
Oxygen Toxicity Prolonged exposure to FiO2 > 0.60 damages the alveolar epithelium through free radical-mediated injury. Targets should keep FiO2 as low as possible while maintaining adequate oxygenation.
ICU-Acquired Weakness (ICUAW) Critical illness polyneuropathy and myopathy affects up to 50% of patients requiring prolonged mechanical ventilation. Prolonged neuromuscular blockade, corticosteroids, hyperglycemia, immobility, and sepsis are risk factors. Affected patients are difficult to wean from ventilation and have prolonged rehabilitation needs.
Tracheal Complications Prolonged intubation leads to tracheal mucosal pressure necrosis, post-extubation tracheomalacia, or subglottic stenosis. Tracheostomy is considered after 10–14 days of mechanical ventilation to improve patient comfort, reduce sedation requirements, facilitate weaning, and allow oral feeding.
Hemodynamic Effects of PEEP High PEEP increases intrathoracic pressure, reducing venous return to the right heart (preload reduction), compressing the pulmonary vasculature (increasing right ventricular afterload), and potentially shifting the interventricular septum leftward. Close hemodynamic monitoring is essential when PEEP is escalated.

10.2 Weaning from Mechanical Ventilation

Once the underlying cause of ARF is resolving, active weaning should begin. Assessment criteria for readiness to wean include:
  • Cause of respiratory failure improving
  • PaO2/FiO2 > 150–200 with PEEP ≤ 5–8 cm H2O and FiO2 ≤ 0.40–0.50
  • Hemodynamic stability without vasopressors (or minimal support)
  • Adequate mentation (able to follow simple commands)
  • Adequate cough and ability to manage secretions
Spontaneous Breathing Trial (SBT): The cornerstone of weaning. The patient is allowed to breathe spontaneously through the endotracheal tube with minimal support (T-piece or low-level pressure support 5–8 cm H2O) for 30–120 minutes. Signs of failure: tachypnea (RR > 35), desaturation, distress, diaphoresis, hemodynamic instability. If tolerated, the patient proceeds to extubation.
The Rapid Shallow Breathing Index (RSBI) = RR / Vt (in liters). A value < 105 breaths/min/L predicts successful extubation; > 105 predicts failure.

10.3 Prognosis

Prognosis in ARF depends critically on the underlying etiology, severity of gas exchange impairment, and extent of multi-organ dysfunction:
  • Acute severe asthma: mortality < 1% with appropriate management
  • COPD exacerbation requiring ventilation: in-hospital mortality 20–30%; 1-year mortality up to 43%
  • Community-acquired pneumonia requiring ICU: mortality 20–30%
  • Cardiogenic pulmonary edema: depends on underlying cardiac function; good prognosis if reversible cause
  • ARDS: overall in-hospital mortality 35–45%; severe ARDS (P/F ≤ 100) carries 45–55% mortality despite modern lung-protective strategies
  • Predictors of poor outcome in ARDS: older age, non-pulmonary organ dysfunction, sepsis as precipitant, higher severity scores (APACHE II > 25), low static compliance

10.4 Long-Term Outcomes in ARDS Survivors

ARDS survivors face a complex array of long-term problems:
  • Pulmonary: mild restrictive defect with reduced DLCO in most survivors; resolves partially over 12 months in most
  • Neurocognitive: cognitive impairment (memory, attention, executive function) in up to 70% of survivors at 2 years — thought to be related to hypoxemia, sedation, and inflammation affecting the brain
  • Psychiatric: PTSD in 30–50%, depression in up to 40%, anxiety disorders
  • Physical: ICU-acquired weakness, reduced exercise capacity, sarcopenia
  • Post-Intensive Care Syndrome (PICS): umbrella term for the constellation of cognitive, psychological, and physical impairments persisting after ICU discharge
Early rehabilitation, structured follow-up in post-ICU clinics, psychological support, and nutritional optimization are central to improving long-term outcomes.
Source: Goldman-Cecil Medicine International Edition; Fishman's Pulmonary Diseases and Disorders, 2-Volume Set; Mulholland and Greenfield's Surgery: Scientific Principles and Practice 7e; Barash, Cullen, and Stoelting's Clinical Anesthesia 9e

11. NUTRITIONAL SUPPORT IN ACUTE RESPIRATORY FAILURE

Critically ill patients with ARF are in a hypermetabolic state driven by the underlying disease, inflammatory response, and increased work of breathing. Nutritional support is integral to ICU care and influences outcomes including weaning success:
  • Enteral nutrition is preferred over parenteral when the gastrointestinal tract is functional; it preserves gut mucosal integrity and reduces infectious complications
  • Energy provision: 25–30 kcal/kg/day in most patients
  • Protein: 1.2–2.0 g/kg/day; up to 2.5 g/kg/day in patients on continuous renal replacement therapy
  • Carbohydrate-fat balance: Early enthusiasm for high-fat, low-carbohydrate formulas to reduce CO2 production proved valid only in overfed patients; standard formulations are appropriate for normally-fed patients
  • Avoid overfeeding: CO2 production is proportional to substrate oxidation. Overfeeding, particularly with carbohydrates, increases VCO2 and minute ventilation requirements, potentially prolonging ventilator dependence
  • Fluid-restricted formulas: Indicated in patients with fluid overload
Source: Mulholland and Greenfield's Surgery: Scientific Principles and Practice 7e

12. SUMMARY TABLE

FeatureType I (Hypoxemic ARF)Type II (Hypercapnic ARF)
PaO2< 60 mm Hg< 60 mm Hg
PaCO2Normal or low> 45 mm Hg
pHNormal or elevatedAcidotic (< 7.35)
A-a gradientWidenedNormal (if pure hypoventilation)
Primary mechanismV/Q mismatch, shunt, diffusionPump failure, hypoventilation
Common examplesPneumonia, ARDS, pulmonary edemaCOPD exacerbation, asthma, GBS
Response to O2Good (V/Q mismatch); poor (shunt)Good but must be controlled
NIV roleHFNC, CPAP, selective BiPAPBiPAP strongly indicated in COPD
Lung-protective ventilationCentral (ARDS)Less central but avoid overdistension

REFERENCES

  1. Goldman-Cecil Medicine International Edition, 2-Volume Set (Chapter 90: Acute Respiratory Failure) — Elsevier
  2. Fishman's Pulmonary Diseases and Disorders, 2-Volume Set (Chapter 139: Respiratory Failure: An Overview) — McGraw-Hill
  3. Mulholland and Greenfield's Surgery: Scientific Principles and Practice, 7e — Lippincott
  4. Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e — Lippincott
  5. Murray & Nadel's Textbook of Respiratory Medicine, 2-Volume — Elsevier
  6. ARDS Network. Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for ALI and ARDS. N Engl J Med 2000;342:1301–1308
  7. Guérin C et al. (PROSEVA). Prone Positioning in Severe ARDS. N Engl J Med 2013;368:2159–2168
  8. ARDS Definition Task Force. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA 2012;307:2526–2533
These notes are sourced from authoritative medical textbooks and cover the full scope of Acute Lung Failure for academic project work.
This is a shared conversation. Sign in to Orris to start your own chat.